Background: Treatment for metastatic neuroendocrine tumors (NETs) is often with somatostatin analogues (SSA) such as lanreotide in the first-line setting. Real world use of lanreotide in Canada is not well studied.
Methods: We performed a retrospective chart review of 69 patients to study real world use of lanreotide at our centre.
Results: Lanreotide was the first-line of systemic treatment in 60 patients. Watch-and-wait was a common strategy and was seen in 31 patients. SSA switch strategy was seldom applied. Majority of patients on lanreotide had low-grade NETs. Standard starting dose of lanreotide 120 mg every 28 days was used in 66 patients. Dose escalation to 120 mg every 21 days occurred in 7 patients. The primary intention for treatment was tumor control in 32 patients, and both tumor and symptom control in 34 patients. Median time on treatment was 21.6 months.
Conclusions: Overall, our findings were in keeping with current guidelines. It will be interesting to assess how clinical practice evolves in the future and to determine the role of dose escalation for disease control.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10331746 | PMC |
| http://dx.doi.org/10.21037/jgo-22-1182 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Real-Life Data on the Safety of Pasireotide in Acromegaly: Insights from EudraVigilance.
Pharmaceuticals (Basel)
December 2024
Preclinical Department, Faculty of Medicine, "Lucian Blaga" University of Sibiu, 550169 Sibiu, Romania.
Background/objectives: Pasireotide (PAS) is a somatostatin receptor ligand (SRL) used to treat acromegaly, a chronic condition caused by excess growth hormone. While it offers significant benefits as a second-line treatment for uncontrolled acromegaly, its use raises major concerns due to hyperglycemic side effects and gastrointestinal issues, the latter being similar to those seen with first-generation SRLs. The aim of this study is to evaluate the real-world evidence on adverse drug reactions (ADRs) reported for PAS in the EudraVigilance database, in comparison to other established drug-based therapies for acromegaly.
View Article and Find Full Text PDFIntraoperative intermittently scanned continuous glucose monitoring in the management of patients with pancreatic insulinoma.
J Endocrinol Invest
October 2024
Endocrine Unit, Department of Clinical and Experimental Medicine, Garibaldi-Nesima Hospital, University of Catania, Catania, Italy.
Article Synopsis
- * A study used an intermittently scanned continuous glucose monitoring (isCGM) device during surgery on five insulinoma patients to assess real-time glucose fluctuations for better surgical outcomes.
- * Results showed that isCGM effectively indicated complete tumor excision, with varying glucose responses based on pre-treatment, suggesting it could become a standard tool in insulinoma surgery if validated in larger studies.
Low to intermediate grade lung neuroendocrine tumours. A single centre real world experience.
Cancer Treat Res Commun
December 2024
University of Ottawa Division of Medical Oncology, Ottawa, Ontario, Canada; The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada; The Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
Article Synopsis
- - Lung neuroendocrine tumors (LNETs) are rare and increasingly diagnosed tumors, and this study examines their diagnosis, treatment, and survival trends among patients with low to intermediate grades.
- - A review of 59 patients revealed that surgical treatment led to significantly better five-year overall survival (83%) compared to non-surgical options (44%), although metastatic disease had a poor prognosis (39% survival for stage IV).
- - The study emphasizes that while there are multiple treatment options, the lack of established guidelines for treatment sequencing indicates a need for improved evidence-based practices in managing LNETs.
Long-term experience with octreotide and lanreotide for the treatment of gastroenteropancreatic neuroendocrine tumors.
Clin Transl Oncol
September 2024
Department of Medicine I, Division of Oncology, Medical University of Vienna, Waehringer Guertel 18-20, A-1090, Vienna, Austria.
Introduction: The somatostatin analogs (SSA) octreotide and lanreotide are a mainstay in the treatment of neuroendocrine tumors (NET). The two pivotal trials differed considerably in terms of patient characteristics and are not directly comparable. Further comparative data are lacking.
View Article and Find Full Text PDFReal-World Study of Lanreotide Autogel in Routine Practice in Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) in Hong Kong and Taiwan.
Oncol Ther
August 2024
Department of Oncology, Taipei Veterans General Hospital, Taipei City, 11217, Taiwan.
Introduction: There is a lack of data on the efficacy, effectiveness, and safety of lanreotide autogel in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) of Chinese ethnicity. This noninterventional, retrospective study evaluated the effectiveness and safety of lanreotide autogel in patients of Chinese ethnicity with GEP-NETs in clinical practice.
Methods: Patients' charts were abstracted from five hospitals in Hong Kong and Taiwan (July-September 2021), where lanreotide autogel is approved for treating GEP-NETs.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!